Neurocrine Biosciences annual gross margin
2015
2016
2017
2018
2020
2021
2022
2023
2024
2025
Neurocrine Biosciences Gross Margin Growth & History (NBIX)
Neurocrine Biosciences's gross margin was 98.18% for fiscal 2025.
View full Neurocrine Biosciences company overviewNeurocrine Biosciences annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 98.18% | −0.38 pp |
| 2024 | 2024-12-31 | 98.56% | +0.66 pp |
| 2023 | 2023-12-31 | 97.90% | −0.55 pp |
| 2022 | 2022-12-31 | 98.44% | −0.30 pp |
| 2021 | 2021-12-31 | 98.74% | −0.30 pp |
| 2020 | 2020-12-31 | 99.03% | — |
| 2018 | 2018-12-31 | 98.92% | −0.31 pp |
| 2017 | 2017-12-31 | 99.22% | −0.78 pp |
| 2016 | 2016-12-31 | 100.00% | 0.00 pp |
| 2015 | 2015-12-31 | 100.00% | — |
Neurocrine Biosciences quarterly gross margin
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 97.58% | −0.78 pp |
| Q1 2026 | 2026-03-31 | 98.31% | −0.09 pp |
| Q4 2025 | 2025-12-31 | 97.82% | −0.70 pp |
| Q3 2025 | 2025-09-30 | 98.24% | −0.48 pp |
| Q2 2025 | 2025-06-30 | 98.36% | −0.08 pp |
| Q1 2025 | 2025-03-31 | 98.39% | −0.15 pp |
| Q4 2024 | 2024-12-31 | 98.52% | +0.17 pp |
| Q3 2024 | 2024-09-30 | 98.71% | +0.96 pp |
| Q2 2024 | 2024-06-30 | 98.44% | +0.98 pp |
| Q1 2024 | 2024-03-31 | 98.54% | +0.57 pp |
| Q4 2023 | 2023-12-31 | 98.35% | +0.22 pp |
| Q3 2023 | 2023-09-30 | 97.75% | −0.67 pp |
| Q2 2023 | 2023-06-30 | 97.46% | −1.27 pp |
| Q1 2023 | 2023-03-31 | 97.98% | −0.54 pp |
| Q4 2022 | 2022-12-31 | 98.13% | −0.55 pp |
| Q3 2022 | 2022-09-30 | 98.43% | −0.15 pp |
| Q2 2022 | 2022-06-30 | 98.73% | −0.20 pp |
| Q1 2022 | 2022-03-31 | 98.52% | −0.26 pp |
| Q4 2021 | 2021-12-31 | 98.69% | −0.14 pp |
| Q3 2021 | 2021-09-30 | 98.58% | −0.37 pp |
| Q2 2021 | 2021-06-30 | 98.93% | −0.28 pp |
| Q1 2021 | 2021-03-31 | 98.77% | −0.34 pp |
| Q4 2020 | 2020-12-31 | 98.83% | — |
| Q3 2020 | 2020-09-30 | 98.96% | −0.05 pp |
| Q2 2020 | 2020-06-30 | 99.21% | +0.08 pp |
| Q1 2020 | 2020-03-31 | 99.11% | −0.07 pp |
| Q3 2019 | 2019-09-30 | 99.01% | +0.03 pp |
| Q2 2019 | 2019-06-30 | 99.13% | +0.01 pp |
| Q1 2019 | 2019-03-31 | 99.18% | +0.52 pp |
| Q4 2018 | 2018-12-31 | 98.80% | −0.39 pp |
| Q3 2018 | 2018-09-30 | 98.98% | −0.31 pp |
| Q2 2018 | 2018-06-30 | 99.12% | +0.08 pp |
| Q1 2018 | 2018-03-31 | 98.66% | — |
| Q4 2017 | 2017-12-31 | 99.20% | — |
| Q3 2017 | 2017-09-30 | 99.29% | — |
| Q2 2017 | 2017-06-30 | 99.04% | — |
Neurocrine Biosciences gross margin trends
Over the last five fiscal years, Neurocrine Biosciences's gross margin decreased from 99.03% to 98.18%, a change of −0.86 percentage points. The latest reported quarter, Q2 2026, shows 97.58%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Neurocrine Biosciences source filings ↗